ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AVTX vs ALT // EV/EBITDA & P/E VALUATION

Avalo Therapeutics Inc. (NASDAQ) VS. Altimmune Inc. (NASDAQ) • 15-METRIC TALLY: AVTX 1 — ALT 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AVTX VS. ALT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AVTX ALT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -34.70% -0.30 ALT /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -12.90% -16.23% +3.33 AVTX /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -65.00% 105.00% -170.00 ALT /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.66 1.30 -0.64 ALT /balance-sheet <GO>
Piotroski F-Score Quality 2/9 5/9 -3.00 ALT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 22.6 26.7 -4.05 ALT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $399.0M $416.3M -$17.3M ALT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AVTX REV ALT REV AVTX GROSS % ALT GROSS % AVTX FCF ALT FCF
FY 2025 $59.0K $41.0K — — -$51.5M -$67.5M
FY 2024 $441.0K $20.0K — — -$49.1M -$79.8M
FY 2023 $1.9M $426.0K — — -$30.7M -$75.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AVTX // BETA —
ALT // BETA —